Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)

被引:87
|
作者
Abdulla, Alan [1 ]
Dijkstra, Annemieke [2 ]
Hunfeld, Nicole G. M. [1 ,3 ]
Endeman, Henrik [3 ]
Bahmany, Soma [1 ]
Ewoldt, Tim M. J. [3 ]
Muller, Anouk E. [4 ,5 ]
van Gelder, Teun [6 ]
Gommers, Diederik [3 ]
Koch, Birgit C. P. [1 ]
机构
[1] Erasmus Univ, Med Ctr, Dept Hosp Pharm, POB 2040, NL-3000 CA Rotterdam, Netherlands
[2] Maasstad Hosp, Dept Intens Care, Rotterdam, Netherlands
[3] Erasmus Univ, Med Ctr, Dept Intens Care, Rotterdam, Netherlands
[4] Erasmus Univ, Med Ctr, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands
[5] Haaglanden Med Ctr, Dept Med Microbiol, The Hague, Netherlands
[6] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands
来源
CRITICAL CARE | 2020年 / 24卷 / 01期
关键词
Beta-lactam; Critically ill patients; Pharmacokinetics; Pharmacodynamics; Target attainment; Risk factors; AUGMENTED RENAL CLEARANCE; MINIMUM INHIBITORY CONCENTRATION; INTENSIVE-CARE-UNIT; CEFEPIME PLASMA-CONCENTRATIONS; ANTIMICROBIAL THERAPY; PHARMACODYNAMICS; SEPSIS; PHARMACOKINETICS; PREDICTORS; MEROPENEM;
D O I
10.1186/s13054-020-03272-z
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Early and appropriate antibiotic dosing is associated with improved clinical outcomes in critically ill patients, yet target attainment remains a challenge. Traditional antibiotic dosing is not suitable in critically ill patients, since these patients undergo physiological alterations that strongly affect antibiotic exposure. For beta-lactam antibiotics, the unbound plasma concentrations above at least one to four times the minimal inhibitory concentration (MIC) for 100% of the dosing interval (100%integral T > 1-4xMIC) have been proposed as pharmacodynamic targets (PDTs) to maximize bacteriological and clinical responses. The objectives of this study are to describe the PDT attainment in critically ill patients and to identify risk factors for target non-attainment. Methods: This prospective observational study was performed in two ICUs in the Netherlands. We enrolled adult patients treated with the following beta-lactam antibiotics: amoxicillin (with or without clavulanic acid), cefotaxime, ceftazidime, ceftriaxone, cefuroxime, and meropenem. Based on five samples within a dosing interval at day 2 of therapy, the time unbound concentrations above the epidemiological cut-off (integral T > MICECOFF and integral T > 4xMIC(ECOFF)) were determined. Secondary endpoints were estimated multivariate binomial and binary logistic regression models, for examining the association of PDT attainment with patient characteristics and clinical outcomes. Results: A total of 147 patients were included, of whom 63.3% achieved PDT of 100% integral T > MICECOFF and 36.7% achieved 100% integral T > 4xMIC(ECOFF). Regression analysis identified male gender, estimated glomerular filtration rate (eGFR) >= 90 mL/min/1.73 m(2), and high body mass index (BMI) as risk factors for target non-attainment. Use of continuous renal replacement therapy (CRRT) and high serum urea significantly increased the probability of target attainment. In addition, we found a significant association between the 100% integral T > MICECOFF target attainment and ICU length of stay (LOS), but no significant correlation was found for the 30-day survival. Conclusions Traditional beta-lactam dosing results in low target attainment in the majority of critically ill patients. Male gender, high BMI, and high eGFR were significant risk factors for target non-attainment. These predictors, together with therapeutic drug monitoring, may help ICU clinicians in optimizing beta-lactam dosing in critically ill patients.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis
    Abdul-Aziz, Mohd H.
    Sulaiman, Helmi
    Mat-Nor, Mohd-Basri
    Rai, Vineya
    Wong, Kang K.
    Hasan, Mohd S.
    Abd Rahman, Azrin N.
    Jamal, Janattul A.
    Wallis, Steven C.
    Lipman, Jeffrey
    Staatz, Christine E.
    Roberts, Jason A.
    INTENSIVE CARE MEDICINE, 2016, 42 (10) : 1535 - 1545
  • [22] Incidence and Predictive Factors Associated with Beta-Lactam Neurotoxicity in the Critically Ill: A Retrospective Cohort Study
    Haddad, Natalie A.
    Schreier, Diana J.
    Fugate, Jennifer E.
    Gajic, Ognjen
    Hocker, Sara E.
    Ice, Calvin J.
    Leung, Sarah B.
    Mara, Kristin C.
    Rabinstein, Alejandro A.
    Rule, Andrew D.
    Barreto, Erin F.
    NEUROCRITICAL CARE, 2022, 37 (01) : 73 - 80
  • [23] Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Burns Patients-A One-Year Prospective Study
    Patel, Bhavik M.
    Paratz, Jennifer
    See, Natalie C.
    Muller, Michael J.
    Rudd, Michael
    Paterson, David
    Briscoe, Scott E.
    Ungerer, Jacobus
    McWhinney, Brett C.
    Lipman, Jeffrey
    Roberts, Jason A.
    THERAPEUTIC DRUG MONITORING, 2012, 34 (02) : 160 - 164
  • [24] Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients
    Kaska, Milan
    Havel, Eduard
    Selke-Krulichova, Iva
    Safranek, Petr
    Bezouska, Jan
    Martinkova, Jirina
    BIOMEDICAL PAPERS-OLOMOUC, 2018, 162 (03): : 219 - 226
  • [25] Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis
    Mohd H. Abdul-Aziz
    Helmi Sulaiman
    Mohd-Basri Mat-Nor
    Vineya Rai
    Kang K. Wong
    Mohd S. Hasan
    Azrin N. Abd Rahman
    Janattul A. Jamal
    Steven C. Wallis
    Jeffrey Lipman
    Christine E. Staatz
    Jason A. Roberts
    Intensive Care Medicine, 2016, 42 : 1535 - 1545
  • [26] An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric -lactam therapy
    Imani, Sahand
    Buscher, Hergen
    Day, Richard
    Gentili, Sheridan
    Jones, Graham R. D.
    Marriott, Debbie
    Norris, Ross
    Sandaradura, Indy
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (11) : 2171 - 2175
  • [27] Risk factors for candidaemia in critically ill patients:: a prospective surveillance study
    Jorda-Marcos, Ricard
    Alvarez-Lerma, Francisco
    Jurado, Maite
    Palomar, Mercedes
    Nolla-Salas, Juan
    Leon, Maria A.
    Leon, Cristobal
    MYCOSES, 2007, 50 (04) : 302 - 310
  • [28] Continuous infusion of beta-lactam antibiotics in critically ill patients with sepsis: implementation considerations
    Barton, Greg
    Rickard, Claire M.
    Roberts, Jason A.
    INTENSIVE CARE MEDICINE, 2024, 50 (12) : 2150 - 2153
  • [29] Update on Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Critically Ill Patients-A Narrative Review
    Stasek, Jan
    Keller, Filip
    Koci, Veronika
    Klucka, Jozef
    Klabusayova, Eva
    Wiewiorka, Ondrej
    Strasilova, Zuzana
    Benovska, Miroslava
    Skardova, Marketa
    Malaska, Jan
    ANTIBIOTICS-BASEL, 2023, 12 (03):
  • [30] Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study
    Ehmann, Lisa
    Zoller, Michael
    Minichmayr, Iris K.
    Scharf, Christina
    Maier, Barbara
    Schmitt, Maximilian V.
    Hartung, Niklas
    Huisinga, Wilhelm
    Vogeser, Michael
    Frey, Lorenz
    Zander, Johannes
    Kloft, Charlotte
    CRITICAL CARE, 2017, 21